HUP9900849A2 - Eljárás danazol által kiváltott csonttömegvesztés minimalizálására alkalmas gyógyszerkészítmények előállítása - Google Patents

Eljárás danazol által kiváltott csonttömegvesztés minimalizálására alkalmas gyógyszerkészítmények előállítása

Info

Publication number
HUP9900849A2
HUP9900849A2 HU9900849A HUP9900849A HUP9900849A2 HU P9900849 A2 HUP9900849 A2 HU P9900849A2 HU 9900849 A HU9900849 A HU 9900849A HU P9900849 A HUP9900849 A HU P9900849A HU P9900849 A2 HUP9900849 A2 HU P9900849A2
Authority
HU
Hungary
Prior art keywords
compound
general formula
pyrrolidinyl
danazol
methods
Prior art date
Application number
HU9900849A
Other languages
English (en)
Inventor
George J. Cullinan
Steven A. Fontana
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9900849A2 publication Critical patent/HUP9900849A2/hu
Publication of HUP9900849A3 publication Critical patent/HUP9900849A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány tárgya eljárás gyógyszer előállítására a (II) képletűvegyület vagy annak valamely gyógyászatilag elfőgadható sója általkiváltőtt csőnttömegvesztés minimalizálására, a (II) képletűvegyületet hatékőny mennyiségű, (I) általánős képletű vegyülettel,ahől az (I) általánős képletben R1 szűbsztitűensek jelentése egymástól függetlenül -H, -OH, -O(1-4szénatőmős alkilcsőpőrt), -OCOC6H5, -OCO(1-6 szénatőmős alkilcsőpőrt)vagy -OSO2(4-6 szénatőmős alkilcsőpőrt); és R2 jelentése 1-piperidinilcsőpőrt, 1-pirrőlidinilcsőpőrt, metil-1-pirrőlidinil-csőpőrt, dimetil-1-pirrőlidinil-csőpőrt, 4-mőrfőlinő-csőpőrt, dimetil-aminő-csőpőrt, dietil-aminő-csőpőrt vagy 1-hexametilén-iminő-csőpőrt; vagy annak valamely gyógyászatilagelfőgadható sójával egy időben vagy egymásűtánban alkalmazzák. Atalálmány tárgya tővábbá eljárás a (II) általánős képletű vegyületáltal kiváltőtt csőnttömegveszteség minimalizálására őly módőn, hőgyvalamely csőntanabőlikűs szert a (II) általánős képletű vegyületadagőlásával egy időben vagy egymásűtánban alkalmaznak. A találmánytővábbá a hatóanyagőkat tartalmazó gyógyszerkészítményekre isvőnatkőzik. ŕ
HU9900849A 1995-06-06 1996-06-05 Methods for preparing pharmaceutical compositions for minimizing bone loss effect of danazol HUP9900849A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/467,475 US5599822A (en) 1995-06-06 1995-06-06 Methods for minimizing bone loss

Publications (2)

Publication Number Publication Date
HUP9900849A2 true HUP9900849A2 (hu) 1999-09-28
HUP9900849A3 HUP9900849A3 (en) 1999-11-29

Family

ID=23855853

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900849A HUP9900849A3 (en) 1995-06-06 1996-06-05 Methods for preparing pharmaceutical compositions for minimizing bone loss effect of danazol

Country Status (22)

Country Link
US (1) US5599822A (hu)
EP (1) EP0747054B1 (hu)
JP (1) JPH11507051A (hu)
KR (1) KR19990022498A (hu)
CN (1) CN1192145A (hu)
AU (1) AU696209B2 (hu)
BR (1) BR9608389A (hu)
CA (1) CA2223055A1 (hu)
CO (1) CO4700446A1 (hu)
CZ (1) CZ382997A3 (hu)
DE (1) DE69623074T2 (hu)
EA (1) EA000763B1 (hu)
ES (1) ES2181849T3 (hu)
HU (1) HUP9900849A3 (hu)
IL (1) IL118590A (hu)
NO (1) NO975581L (hu)
PL (1) PL323935A1 (hu)
TR (1) TR199701507T1 (hu)
TW (1) TW372969B (hu)
WO (1) WO1996039138A1 (hu)
YU (1) YU34396A (hu)
ZA (1) ZA964778B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
WO2001035946A2 (en) * 1999-11-15 2001-05-25 New Millennium Pharmaceutical Research, Inc. Intranasal administration of raloxifene and tamoxifen
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1180364A1 (en) * 2000-08-15 2002-02-20 Octagene GmbH Steroid hormones as transfer agents
CN1668303B (zh) 2002-07-22 2010-10-27 伊莱利利公司 含苯磺酰基的选择性雌激素受体调节剂
AU2005247369A1 (en) 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2005112984A2 (en) * 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
EP1931374A2 (en) * 2005-10-06 2008-06-18 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US11253498B2 (en) * 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease
CN108785264A (zh) * 2018-07-03 2018-11-13 威海贯标信息科技有限公司 一种达那唑片剂组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
EP0747054A3 (en) 1997-03-05
ZA964778B (en) 1997-12-08
EA199800013A1 (ru) 1998-06-25
PL323935A1 (en) 1998-04-27
CA2223055A1 (en) 1996-12-12
EA000763B1 (ru) 2000-04-24
CN1192145A (zh) 1998-09-02
WO1996039138A1 (en) 1996-12-12
YU34396A (sh) 1999-07-28
KR19990022498A (ko) 1999-03-25
AU696209B2 (en) 1998-09-03
JPH11507051A (ja) 1999-06-22
TR199701507T1 (xx) 1998-02-21
EP0747054B1 (en) 2002-08-21
HUP9900849A3 (en) 1999-11-29
IL118590A (en) 1999-10-28
AU6043096A (en) 1996-12-24
NO975581D0 (no) 1997-12-03
CZ382997A3 (cs) 1998-09-16
BR9608389A (pt) 1999-05-04
US5599822A (en) 1997-02-04
EP0747054A2 (en) 1996-12-11
DE69623074D1 (de) 2002-09-26
NO975581L (no) 1997-12-03
CO4700446A1 (es) 1998-12-29
TW372969B (en) 1999-11-01
ES2181849T3 (es) 2003-03-01
DE69623074T2 (de) 2003-05-08
IL118590A0 (en) 1996-10-16

Similar Documents

Publication Publication Date Title
HUP9900849A2 (hu) Eljárás danazol által kiváltott csonttömegvesztés minimalizálására alkalmas gyógyszerkészítmények előállítása
ES8202542A1 (es) Procedimiento para la preparacion de sulfonilureas
DE2861729D1 (en) Aliphatic derivatives of phosphonoformic acid, pharmaceutical compositions and methods for combating virus infections
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
ATE154013T1 (de) Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE316083T1 (de) Adamantanderivate
HUP0102602A2 (hu) Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
ES2052028T3 (es) Un metodo para preparar compuestos diarilicos anti-ateroscleroticos.
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
ES476106A1 (es) Procedimiento para la preparacion de 4-espectinomicilamina.
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
HUP0001773A2 (hu) Szubsztituált tetrahidropiridinszármazékok, eljárás előállításukra, továbbá a vegyületeket tartalmazó gyógyászati készítmények
HUP9902119A2 (hu) Difenil-stilbén származékok, mint Cox-2 inhibitorok és ezeket tartalmazó gyógyszerkészítmények
DK163182C (da) Dialkylaminoalkoxybenzylalkoholderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat og fremgangsmaade til fremstilling deraf
ES480113A1 (es) Procedimiento para la preparacion de nuevos derivados de 2- iminoimidazolidina.
DE69330601D1 (de) Serotoninergische ergolin derivate
DE3060423D1 (en) Dipeptides for use in the treatment of diseases, some compounds of this class, medicaments containing dipeptides and their manufacture
NO950177D0 (no) Farmakologisk aktive erivater
IL64839A (en) N-arylmethyl-4-(methylanilino)-5-sulfamoyl-anthranilic acids,a process for their preparation and pharmaceutical compositions containing them
RU92016559A (ru) Производные диалкокси-пиридинилбензимидазола, фармацевтическая композиция, способ ингибирования или лечения, способ их получения, применение и промежуточные соединения
HUP0203182A2 (hu) Diarileninszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk